<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125016</url>
  </required_header>
  <id_info>
    <org_study_id>R4336-ONC-20104</org_study_id>
    <secondary_id>2021-001104-15</secondary_id>
    <nct_id>NCT05125016</nct_id>
  </id_info>
  <brief_title>REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>Phase 1/2 Study of REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is:&#xD;
&#xD;
      Dose Escalation:&#xD;
&#xD;
      • To assess the safety, tolerability, and pharmacokinetics (PK) and to determine recommended&#xD;
      phase 2 dosing regimen (RP2DR) of REGN4336 separately as monotherapy or in combination with&#xD;
      cemiplimab&#xD;
&#xD;
      Dose Expansion:&#xD;
&#xD;
      • To assess preliminary anti-tumor activity of REGN4336 as monotherapy or in combination with&#xD;
      cemiplimab as measured by objective response rate (ORR) per modified Prostate Cancer Working&#xD;
      Group (PCWG3) criteria&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
      Dose Escalation:&#xD;
&#xD;
      • To assess preliminary anti-tumor activity of REGN4336 as monotherapy or in combination with&#xD;
      cemiplimab as measured by ORR per modified PCWG3 criteria&#xD;
&#xD;
      Dose Expansion:&#xD;
&#xD;
        -  To characterize the safety profile in each expansion cohort&#xD;
&#xD;
        -  To characterize the PK of REGN4336 as monotherapy or in combination with cemiplimab&#xD;
&#xD;
      In both Dose Escalation and Dose Expansion:&#xD;
&#xD;
        -  To assess preliminary anti-tumor activity of REGN4336 as monotherapy or in combination&#xD;
           with cemiplimab as measured by prostate specific antigen (PSA) decline&#xD;
&#xD;
        -  To evaluate immunogenicity of REGN4336 in Module 1 and immunogenicity of REGN4336 and&#xD;
           cemiplimab in Module 2&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 19, 2021</start_date>
  <completion_date type="Anticipated">August 4, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 4, 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study contains 2 separate modules in parallel: monotherapy with REGN4336 (Module 1) and combination therapy with REGN4336 and cemiplimab (Module 2). Both modules contain independent dose escalation cohorts and up to 2 recommended phase 2 dose regimens during dose expansion.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>28 days, up to 42 days</time_frame>
    <description>Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of Immune-related Adverse Events (irAEs)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of SAEs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse event of special interests (AESIs)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with grade ≥3 laboratory abnormalities</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>REGN4336 concentrations in serum</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation:&#xD;
As monotherapy or in combination with cemiplimab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR per modified per modified Prostate Cancer Working Group 3 (PCWG3) criteria</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose expansion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR per modified per modified PCWG3 criteria</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose Escalation:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of TEAEs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of Immune-related Adverse Events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of SAEs</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse event of special interests (AESIs)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with grade ≥3 laboratory abnormalities</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>REGN4336 concentrations in serum</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose expansion:&#xD;
As monotherapy or in combination with cemiplimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with ≥50% reduction prostate specific antigen (PSA) from baseline, confirmed by a second PSA test ≥4 weeks later</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation and expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with ≥90% reduction prostate specific antigen (PSA) from baseline, confirmed by a second PSA test ≥4 weeks later</measure>
    <time_frame>UP to 5 years</time_frame>
    <description>Dose escalation and expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies (ADA) to REGN4336</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Module 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA to REGN4336 and cemiplimab</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Module 2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">199</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Module 1- Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN4336</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 2-Combo Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN4336 + Cemiplimab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN4336</intervention_name>
    <description>Administered once weekly (QW) or every 3 weeks (Q3W) by subcutaneous (SC) injection.</description>
    <arm_group_label>Module 1- Monotherapy</arm_group_label>
    <arm_group_label>Module 2-Combo Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cemiplimab</intervention_name>
    <description>Administered concomitantly every 3 weeks (Q3W) by IV infusion</description>
    <arm_group_label>Module 2-Combo Therapy</arm_group_label>
    <other_name>REGN2810</other_name>
    <other_name>Libtayo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-DCFPyL</intervention_name>
    <description>Prostate-specific membrane antigen (PSMA) Positron emission tomography (PET)/Computer tomography (CT) imaging agent to be used at select sites</description>
    <arm_group_label>Module 1- Monotherapy</arm_group_label>
    <arm_group_label>Module 2-Combo Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed adenocarcinoma of the prostate without pure&#xD;
             small cell carcinoma&#xD;
&#xD;
          2. Metastatic, castration-resistant prostate cancer (mCRPC) with PSA value at screening&#xD;
             ≥4 ng/mL that has progressed within 6 months prior to screening as defined in the&#xD;
             protocol&#xD;
&#xD;
          3. Has progressed upon or intolerant to ≥2 lines prior systemic therapy approved in the&#xD;
             metastatic and/or castration-resistant setting (in addition to androgen deprivation&#xD;
             therapy [ADT]) including at least one second-generation anti-androgen therapy (e.g.&#xD;
             abiraterone, enzalutamide, apalutamide, or darolutamide)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Has received treatment with an approved systemic therapy within 3 weeks of dosing or&#xD;
             has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities&#xD;
&#xD;
          2. Has received any previous systemic biologic therapy within 5 half-lives of first dose&#xD;
             of study therapy&#xD;
&#xD;
          3. Has received prior PSMA-targeting therapy&#xD;
&#xD;
          4. Any condition that requires ongoing/continuous corticosteroid therapy (&gt;10 mg&#xD;
             prednisone/day or anti-inflammatory equivalent) within 1 week prior to the first dose&#xD;
             of study therapy&#xD;
&#xD;
          5. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that&#xD;
             required treatment with systemic immunosuppressive treatments&#xD;
&#xD;
          6. Encephalitis, meningitis, neurodegenerative disease (with the exception of mild&#xD;
             dementia that does not interfere with activities of daily living [ADLs]) or&#xD;
             uncontrolled seizures in the year prior to first dose of study therapy&#xD;
&#xD;
          7. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or&#xD;
             hepatitis C infection; or diagnosis of immunodeficiency&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion Criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment-experienced metastatic castration-resistant prostate cancer (mCRPC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

